Skip to main content

abiraterone acetate


Status: One Wales interim decision

Using the agreed starting and stopping criteria, abiraterone in combination with prednisolone can be made available within NHS Wales for the treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer. High risk is defined as at least 2 of the following: tumour stage T3 or T4, a Gleason score of 8 to 10, and a PSA level of ≥ 40 ng/ml.

Abiraterone acetate should be prescribed on the basis of lowest acquisition cost.

The risks and benefits of the off-label use of abiraterone for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with decision rationale and start stop criteria Abiraterone for nmHS prostate cancer. OW20. 2022. (PDF, 113Kb)
 Evidence Status Report. Abiraterone for high risk nmHSPC. OW20. 2022 (PDF, 219Kb)

Medicine details

Medicine name abiraterone acetate
Formulation film-coated tablet
Reference number OW20

Treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer

Company Various
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status One Wales interim decision
Advice number OW20
Date of issue 07/11/2022
Follow AWTTC: